AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11370551
Drug: Postoperative radiochemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiochemotherapy (50.4 Gy total dose, 1.8 Gy single dose, 5-FU 1,000 mg/m2/d for 120 hours in weeks 1 and 5, 4 cycles of 5-FU 500 mg/m2/d i.v. bolus)
Trial: 8215669
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ceftriaxone
Trial: 3302845
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of ceftriaxone
Trial: 26997378
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (100 μg/mL intravenously, two times a week for eight weeks)
Trial: 22737716
Drug: 0.3 mg/5
RxNorm normalized name: Calcium Pantothenate/Cyanocobalamin/Iron/Magnesium/Manganese/Niacin/Pyridoxine/Riboflavin/Thiamine/Zinc 1.67 MG/5 ML-0.00017 MG/5 ML-2.5 MG/5 ML-8.3 MG/5 ML-0.17 MG/5 ML-0.42 MG/5 ML-0.83 MG/5 ML-0.3 MG/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/5 ml scopolamine
Trial: 22737716
Drug: 4 mg/5
RxNorm normalized name: Pediox, 4 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/5 ml ondansetron
Trial: 22737716
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg scopolamine plus 4 mg ondansetron per 5 ml
Trial: 22737716
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline 5 ml (control group)
Trial: 19643947
Drug: SCH527123 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH527123 (50 mg once daily, 4 days)
Trial: 19643947
Drug: Prednisolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (50 mg once)
Trial: 15207942
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and light therapy
Trial: 15207942
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy alone
Trial: 11511559
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg followed by 30 mg four times daily
Trial: 11511559
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 2 g followed by 1 g four times daily
Trial: 11511559
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (lansoprazole and tranexamic acid)
Trial: 9255202
Drug: Aerosolized recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10 mg twice a day for 14 days, followed by a 14-day washout period for a total of 6 treatment cycles.
Trial: 29558034
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of modified Sinaki exercises and Nordic walking
Trial: 23388687
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment once a week
Trial: 23388687
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment twice a week
Trial: 23388687
Drug: Vehicle twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle twice a week
Trial: 17142206
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (OM) 0.4 mg/kg mixed with cherry juice
Trial: 17142206
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (INM) 0.2 mg/kg as drops
Trial: 17142206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral cherry juice or intranasal serum physiologic)
Trial: 14610441
Drug: Individualized daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized daily schedule
Trial: 10910832
Drug: Remifentanil combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil combined with intrathecal morphine (R group)
Trial: 8929583
Drug: Cr (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr (0.5 g x kg‐1 x day‐1)
Trial: 8929583
Drug: Cr (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr (0.5 g x kg‐1 x day‐1) + C (5 mg x kg‐1 x day‐1)
Trial: 1533376
Drug: Danazol 400
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 400 mg/d orally
Trial: 25851776
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate loading (CHL) drinks consumed 12 and 2 hours presurgery, and immediate postoperative peripheral parenteral nutrition.
Trial: 20926754
Drug: BG9928 (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (0.03 mg/kg)
Trial: 20926754
Drug: BG9928 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (0.3 mg/kg)
Trial: 20926754
Drug: BG9928 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (1.0 mg/kg)
Trial: 20926754
Drug: BG9928 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (3.0 mg/kg)
Trial: 16954936
Drug: High-concentration contrast
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration contrast medium (370 mg I/mL)
Trial: 16954936
Drug: Low-concentration contrast
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration contrast medium (300 mg I/mL)
Trial: 15250771
Drug: Multiple treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple treatments with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Trial: 15250771
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Trial: 9171066
Drug: Low-dose m-BACOD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose m-BACOD with GM-CSF (n=98)
Trial: 9171066
Drug: Standard-dose m-BACOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose m-BACOD with GM-CSF (n=94)
Trial: 24075427
Drug: Enoxaparin in
RxNorm normalized name: enoxaparin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin in balanced salt solution (BSS)
Trial: 16424718
Drug: Alanyl-glutamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl-glutamine (0.4 g x kg body weight(-1) x 24 hrs(-1))
Trial: 12829670
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose radiotherapy (50.4 Gy in 28 fractions)
Trial: 12829670
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose radiotherapy (64.8 Gy in 36 fractions)
Trial: 12829670
Drug: Radiotherapy (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (both doses)
Trial: 9607553
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal treatment (NHT) with leuprolide plus cyproterone acetate
Trial: 319424
Drug: Indomethacin +
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin + aspirin (150 mg indomethacin daily, 1500 mg aspirin daily)
Trial: 15955382
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg/day)
Trial: 31339011
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg/day)
Trial: 10333347
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg
Trial: 17459221
Drug: Ulinastatin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (300 K units per day) + thymosin alpha1 (Maipuxin, 1.6 mg per day) for 7 days (treatment group 1)
Trial: 17459221
Drug: Double dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dosage of Ulinastatin and thymosin alpha1 (treatment group 2)
Trial: 15141331
Drug: Oral DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral DFMO at 100 mg/kg body weight every 6 h for 14 days
Trial: 15141331
Drug: Oral DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral DFMO at 125 mg/kg body weight every 6 h for 14 days
Trial: 15141331
Drug: Oral DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral DFMO at 100 mg/kg
Trial: 15141331
Drug: Oral DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral DFMO at 125 mg/kg
Trial: 30417662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rivaroxaban 2.5 mg twice‐daily and aspirin 100 mg daily
Trial: 30417662
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg twice‐daily alone
Trial: 25148458
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AIs) therapy
Trial: 19955739
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamins (adherence >90% to <99%)
Trial: 19955739
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamins (adherence >=99%)
Trial: 17190130
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and intravenous antibiotherapy
Trial: 17190130
Drug: Internal medicine/infectious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine/infectious diseases department
Trial: 26779855
Drug: Tapering clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering clopidogrel discontinuation during a two‐week period (n = 25)
Trial: 25561347
Drug: Endometrial scratching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial scratching (biopsy procedure twice)
Trial: 15983147
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg added to lidocaine infiltration
Trial: 15983147
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg injected subcutaneously in the contralateral abdominal wall (Control)
Trial: 12923398
Drug: Acetylsalicylate-lysin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylate-lysin (500 mg intravenously)
Trial: 12923398
Drug: Parecoxib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (20 mg intravenously)
Trial: 10540095
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg plus dexamethasone 5 mg
Trial: 9103076
Drug: Cell free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell free staphylococcal vaccine
Trial: 9103076
Drug: Commercial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial preparation of staphylococcal antiphagin (Control Group 1)
Trial: 9103076
Drug: Traditional methods
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional methods without vaccines (Control Group 2)
Trial: 6678385
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of clonidine hydrochloride (Group 1)
Trial: 6678385
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of clonidine hydrochloride (Group 2)
Trial: 31919579
Drug: Bilastine 10
RxNorm normalized name: Bilastine 10 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 10 mg/day
Trial: 30472992
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal treatment (IPT) including whole mouth subgingival scaling, surgical periodontal therapy (if good oral hygiene), and supportive periodontal therapy every 3 months.
Trial: 30472992
Drug: Control periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control periodontal treatment (CPT) including supra-gingival scaling and polishing at the same timepoints as in the IPT group.
Trial: 30472992
Drug: Control periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control periodontal treatment (CPT)
Trial: 22691021
Drug: Forgiveness treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgiveness treatment (n=41)
Trial: 22691021
Drug: Anger-reduction treatment
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anger-reduction treatment (n=39)
Trial: 18548293
Drug: Conventional nonsurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional nonsurgical treatment
Trial: 15370078
Drug: L-Arginine (L-Arg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (L-Arg 20 g/500 ml)
Trial: 11080405
Drug: dimenhydrinate 50
RxNorm normalized name: dimenhydrinate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimenhydrinate 50 mg IV
Trial: 9396185
Drug: Meta-analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analysis of treatments
Trial: 24704801
Drug: Pre‐emptive methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive methylprednisolone infusion (5 mg/kg) before radiotherapy (Group 1)
Trial: 24704801
Drug: Short‐course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short‐course radiotherapy without methylprednisolone infusion (Group 2)
Trial: 24704801
Drug: Pre‐emptive methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive methylprednisolone infusion (Group 1)
Trial: 15869338
Drug: Empirically supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirically supported treatments (ESTs)
Trial: 12592686
Drug: Astragalus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus injection (20 ml in 250 ml of normal saline, once per day for 21 days, 4 courses)
Trial: 10342509
Drug: Terlipressin-glycerin trinitrate
RxNorm normalized name: Glycerin trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin-glycerin trinitrate combination (TER-GTN)
Trial: 8564726
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg/die for 7 days)
Trial: 1720262
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aprotinin (2 million KIU after induction of anesthesia followed by 500,000 KIU/h infusion throughout the operation)
Trial: 31852355
Drug: 6-grass-pollen-allergoid (Allergovit®)
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-grass-pollen-allergoid (Allergovit®) treatment initiated during pollen season (Group-A)
Trial: 31852355
Drug: 6-grass-pollen-allergoid (Allergovit®)
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-grass-pollen-allergoid (Allergovit®) treatment initiated outside pollen season (Group-B)
Trial: 25495666
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy tablet (SLIT-tablet) MK-7243 (2800 BAU/75 000 SQ-T)
Trial: 25331064
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue injection
Trial: 22342469
Drug: Oral danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral danazol 600mg
Trial: 16222884
Drug: FGF 1
RxNorm normalized name: Fibroblast Growth Factor 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF 1 l/min
Trial: 16222884
Drug: FGF 2
RxNorm normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF 2 l/min
Trial: 16222884
Drug: FGF 4
RxNorm normalized name: Fibroblast Growth Factor 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF 4 l/min
Trial: 10431937
Drug: Self-monitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring intervention with additional phone calls and daily mailings during the holiday season
Trial: 10431937
Drug: Standard weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weekly cognitive-behavioral treatment for obesity (comparison group)
Trial: 7589022
Drug: Dipyrone 2
RxNorm normalized name: dipyrone 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 2 g i.m.
Trial: 7589022
Drug: Dipyrone 2
RxNorm normalized name: dipyrone 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 2 g i.v.
Trial: 7589022
Drug: Dipyrone 1
RxNorm normalized name: dipyrone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 1 g i.m.
Trial: 7589022
Drug: Dipyrone 1
RxNorm normalized name: dipyrone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 1 g i.v.
Trial: 7589022
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg i.m.
Trial: 7589022
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg i.v.
Trial: 2405777
Drug: Radiation.MCNU (MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation.MCNU (MR group) with 50-60 Gy irradiation and 2 mg/kg MCNU intravenously on the initial day and 6 weeks later.
Trial: 2405777
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of MCNU and interferon-beta.
Trial: 11777176
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (PGE1)
Trial: 31492661
Drug: Increased abdominal
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased abdominal subcutaneous adipose tissue (ScAT) inflammatory gene expression
Trial: 26718394
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) designed to reduce drinking to cope (DTC) and anxiety symptoms
Trial: 19357642
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg per day)
Trial: 19357642
Drug: Inhaled beclometasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclometasone dipropionate (200 microg per day)
Trial: 20335624
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10-20 mg/d for 4 to 15 months)
Trial: 16270384
Drug: Purple sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple sweet potato leaves (PSPL) diet (daily consumption of 200 g PSPL)
Trial: 11875328
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (25-microg and 50-microg E(2) patch)
Trial: 11875328
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100-microg E(2) patch)
Trial: 11875328
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50-microg E(2) patch combined with P (300 mg/day) or MPA (5 mg/day))
Trial: 11875328
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E(2)) alone